Industry News

A Promising Sign: Pancreatic Cancer Vaccine Sparks Immune Response in 99% of Patients

One of the toughest parts of pancreatic cancer is how often it comes back. Even after surgery and chemotherapy, the disease returns in a large share of patients, which is why researchers are searching for ways to keep it from recurring.

That's the goal behind camupepimut, an investigational vaccine recently studied in a phase 2 trial and published in Nature Medicine. Nearly every patient who received it, about 99%, developed an immune response against mutated KRAS, and in more than 80% of patients that response was over nine times stronger than before vaccination.

It's important to keep these results in perspective. So far, there was no significant difference in disease-free survival between patients who received the vaccine and those who didn't. However, an exploratory analysis suggested patients with the strongest immune responses may have stayed disease-free longer. Other cancer vaccines have shown that strong immune responses can be linked to better survival, which gives researchers reason for hope.

The next phase of research will add booster doses and may test the vaccine alongside other treatments.

Read the full article: https://www.sciencealert.com/new-pancreatic-cancer-vaccine-sparked-immune-responses-in-99-of-patients

The National Pancreas Foundation

The only nonprofit dedicated to all diseases of the pancreas — advancing research, education, and patient care.

Sign up for updates
Explore
Pancreatic DiseasesPatients & CaregiversMedical ProfessionalsGet InvolvedIndustry NewsAbout
Connect
Find a Center of ExcellenceDonateContact
The National Pancreas Foundation is a registered 501(c)(3) nonprofit organization. |  © 2026 The National Pancreas Foundation. All rights reserved. Please send all donations and mail to: The National Pancreas Foundation P.O. Box 750046, Atlanta, GA 30374 U.S.A.